|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Makker V, MacKay H, Ray-Coquard I, Levine
DA, Westin SN, Aoki D and Oaknin A: Endometrial cancer. Nat Rev Dis
Primers. 7:882021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu J, Zhu W, Xia L, Zhu Q, Mao Y, Shen Y,
Li M, Zhang Z and Du J: Identification of CAPG as a potential
prognostic biomarker associated with immune cell infiltration and
ferroptosis in uterine corpus endometrial carcinoma. Front
Endocrinol (Lausanne). 15:14522192024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zou S, Tong Q, Liu B, Huang W, Tian Y and
Fu X: Targeting STAT3 in cancer immunotherapy. Mol Cancer.
19:1452020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma JH, Qin L and Li X: Role of STAT3
signaling pathway in breast cancer. Cell Commun Signal. 18:332020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Y, Liao S, Bennett S, Tang H, Song D,
Wood D, Zhan X and Xu J: STAT3 and its targeting inhibitors in
osteosarcoma. Cell Prolif. 54:e129742021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu Z, Zhang Q, Wei S, Zhang Y, Zhou T,
Zhang Q, Shi R, Zinovkin D, Pranjol ZI, Zhang J and Wang H:
CD146+CAFs promote progression of endometrial cancer by
inducing angiogenesis and vasculogenic mimicry via IL-10/JAK1/STAT3
pathway. Cell Commun Signal. 22:1702024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dong P, Xiong Y, Yue J, Xu D, Ihira K,
Konno Y, Kobayashi N, Todo Y and Watari H: Long noncoding RNA NEAT1
drives aggressive endometrial cancer progression via
miR-361-regulated networks involving STAT3 and tumor
microenvironment-related genes. J Exp Clin Cancer Res. 38:2952019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Viswanadhapalli S, Dileep KV, Zhang KYJ,
Nair HB and Vadlamudi RK: Targeting LIF/LIFR signaling in cancer.
Genes Dis. 9:973–980. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Galoczova M, Coates P and Vojtesek B:
STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett.
23:122018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pan C, Stevic I, Müller V, Ni Q,
Oliveira-Ferrer L, Pantel K and Schwarzenbach H: Exosomal microRNAs
as tumor markers in epithelial ovarian cancer. Mol Oncol.
12:1935–1948. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fabris L, Ceder Y, Chinnaiyan AM, Jenster
GW, Sorensen KD, Tomlins S, Visakorpi T and Calin GA: The potential
of MicroRNAs as prostate cancer biomarkers. Eur Urol. 70:312–322.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu K, Mu XY, Jiang JT, Tan MY, Wang RJ,
Zhou WJ, Wang X, He YY, Li MQ and Liu ZH: miRNA-26a-5p and
miR-26b-5p inhibit the proliferation of bladder cancer cells by
regulating PDCD10. Oncol Rep. 40:3523–3532. 2018.PubMed/NCBI
|
|
14
|
Miyamoto K, Seki N, Matsushita R, Yonemori
M, Yoshino H, Nakagawa M and Enokida H: Tumour-suppressive
miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by
regulating PLOD2 in bladder cancer. Br J Cancer. 115:354–363. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan C, Ding X, Wu L, Yu M, Qu P and Du H:
Stat3 downstream gene product chitinase 3-like 1 is a potential
biomarker of inflammation-induced lung cancer in multiple mouse
lung tumor models and humans. PLoS One. 8:e619842013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singh SK, Bhardwaj R, Wilczynska KM, Dumur
CI and Kordula T: A complex of nuclear factor I–X3 and STAT3
regulates astrocyte and glioma migration through the secreted
glycoprotein YKL-40. J Biol Chem. 286:39893–39903. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z, Wang S, Jia Z, Hu Y, Cao D, Yang
M, Liu L, Gao L, Qiu S, Yan W, et al: YKL-40 derived from
infiltrating macrophages cooperates with GDF15 to establish an
immune suppressive microenvironment in gallbladder cancer. Cancer
Lett. 563:2161842023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hao H, Chen H, Xie L and Liu H: YKL-40
promotes invasion and metastasis of bladder cancer by regulating
epithelial mesenchymal transition. Ann Med. 53:1170–1178. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Böckelmann LC, Felix T, Calabrò S and
Schumacher U: YKL-40 protein expression in human tumor samples and
human tumor cell line xenografts: Implications for its use in tumor
models. Cell Oncol (Dordr). 44:1183–1195. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao T, Su Z, Li Y, Zhang X and You Q:
Chitinase-3 like-protein-1 function and its role in diseases.
Signal Transduct Target Ther. 5:2012020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li L, Fan J, Li D, Liu Y, Shrestha P,
Zhong C, Xia X and Huang X: Influence of YKL-40 gene RNA
interference on the biological behaviors of endometrial cancer
HEC-1A cells. Oncol Lett. 16:1777–1784. 2018.PubMed/NCBI
|
|
22
|
Spitzner M, Roesler B, Bielfeld C, Emons
G, Gaedcke J, Wolff HA, Rave-Fränk M, Kramer F, Beissbarth T, Kitz
J, et al: STAT3 inhibition sensitizes colorectal cancer to
chemoradiotherapy in vitro and in vivo. Int J Cancer. 134:997–1007.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou X, Nie M, Xin X, Hua T, Zhang J, Shi
R, Dong K, Shu W, Yan B and Wang H: RAB17 promotes endometrial
cancer progression by inhibiting TFRC-dependent ferroptosis. Cell
Death Dis. 15:6552024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang X, Cui D, Sun W, Yang G, Wang W and
Mi C: Regulation of the β-catenin/LEF-1 pathway by the siRNA
knockdown of RUVBL1 expression inhibits breast cancer cell
proliferation, migration and invasion. Oncol Rep. 53:222025.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kurien BT and Scofield RH: Western
blotting. Methods. 38:283–293. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu W, Gui S, Peng L, Luo H, Xie J, Xiao J,
Yilamu Y, Sun Y, Cai S, Cheng Z and Tao Z: STAT3-controlled
CHI3L1/SPP1 positive feedback loop demonstrates the spatial
heterogeneity and immune characteristics of glioblastoma. Dev Cell.
60:1751–1767.e9. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Levy DE and Inghirami G: STAT3: A
multifaceted oncogene. Proc Natl Acad Sci USA. 103:10151–10152.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Karras JG, Wang Z, Huo L, Howard RG, Frank
DA and Rothstein TL: Signal transducer and activator of
transcription-3 (STAT3) is constitutively activated in normal,
self-renewing B-1 cells but only inducibly expressed in
conventional B lymphocytes. J Exp Med. 185:1035–1042. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu HH, Leng S, Sergi C and Leng R: How
MicroRNAs command the battle against cancer. Int J Mol Sci.
25:58652024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fan JT, Si XH, Liao Y and Shen P: The
diagnostic and prognostic value of serum YKL-40 in endometrial
cancer. Arch Gynecol Obstet. 287:111–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Banno K, Yanokura M, Kisu I, Yamagami W,
Susumu N and Aoki D: MicroRNAs in endometrial cancer. Int J Clin
Oncol. 18:186–192. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jayaraman M, Radhakrishnan R, Mathews CA,
Yan M, Husain S, Moxley KM, Song YS and Dhanasekaran DN:
Identification of novel diagnostic and prognostic miRNA signatures
in endometrial cancer. Genes Cancer. 8:566–576. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dankner M, Maritan SM, Priego N, Kruck G,
Nkili-Meyong A, Nadaf J, Zhuang R, Annis MG, Zuo D, Nowakowski A,
et al: Invasive growth of brain metastases is linked to CHI3L1
release from pSTAT3-positive astrocytes. Neuro Oncol. 26:10522024.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pouyafar A, Heydarabad MZ, Mahboob S,
Mokhtarzadeh A and Rahbarghazi R: Angiogenic potential of YKL-40 in
the dynamics of tumor niche. Biomed Pharmacother. 100:478–485.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kemik P, Saatli B, Yıldırım N, Kemik VD,
Deveci B, Terek MC, Koçtürk S, Koyuncuoğlu M and Saygılı U:
Diagnostic and prognostic values of preoperative serum levels of
YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol.
140:64–69. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen J, Huang S, Li H, Li Y, Zeng H, Hu J,
Lin Y, Cai H, Deng P, Song T, et al: STAT3 inhibitor BBI608 reduces
patient-specific primary cell viability of cervical and endometrial
cancer at a clinical-relevant concentration. Clin Transl Oncol.
25:662–672. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
van der Zee M, Sacchetti A, Cansoy M,
Joosten R, Teeuwssen M, Heijmans-Antonissen C, Ewing-Graham PC,
Burger CW, Blok LJ and Fodde R: IL6/JAK1/STAT3 signaling blockade
in endometrial cancer affects the ALDHhi/CD126+ stem-like component
and reduces tumor burden. Cancer Res. 75:3608–3622. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gao Y, Qian H, Tang X, Du X, Wang G, Zhang
H, Ye F and Liu T: Superparamagnetic iron oxide
nanoparticle-mediated expression of miR-326 inhibits human
endometrial carcinoma stem cell growth. Int J Nanomedicine.
14:2719–2731. 2019. View Article : Google Scholar : PubMed/NCBI
|
